Iris Isufi, MD
Associate Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Additional Titles
Co-Director Adult CAR T-Cell Therapy Program, Hematology
Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center
Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center
Contact Info
About
Copy Link
Titles
Associate Professor of Medicine (Hematology)
Co-Director Adult CAR T-Cell Therapy Program, Hematology; Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center; Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center
Appointments
Medical Oncology and Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
- Office for CE in Medicine
- Yale Cancer Center
- Yale New Haven Health System
- Yale Ventures
- YCC Collaborative Excellence
Education & Training
- Fellowship
- Yale University School of Medicine (2011)
- Residency
- Albert Einstein College of Medicine/Montefiore Medical Center (2007)
- MD
- State University of New York at Stony Brook (2004)
- BA
- The College of Saint Rose, Biology (2000)
Research
Copy Link
Overview
Dr. Isufi's clinical work has been in the area of hematologic malignancies and autologous and allogeneic stem cell transplantation for these conditions. As part of the lymphoid malignancy and transplant teams, she developed a strong clinical interest in aggressive lymphomas. She has focused her efforts in treating patients with aggressive lymphomas as part of clinical trials and consolidating their response to treatment with either autologous or allogeneic transplant based on specifics of their disease. She has a research interest in early drug development in lymphoma, and has served as local PI for a variety of industry- and cooperative-group-sponsored lymphoma trials, including phase 1 trials.
Medical Research Interests
Bone Marrow Transplantation; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Graft vs Host Disease; Lymphoma; Transplantation Conditioning
Research at a Glance
Yale Co-Authors
Frequent collaborators of Iris Isufi's published research.
Publications Timeline
A big-picture view of Iris Isufi's research output by year.
Research Interests
Research topics Iris Isufi is interested in exploring.
Francine Foss, MD
Stuart Seropian, MD
Scott Huntington, MD, MPH, MSc
Lohith Gowda, MD, MRCP
Shalin Kothari, MD
Michael Girardi, MD, FAAD
29Publications
510Citations
Graft vs Host Disease
Transplantation Conditioning
Lymphoma
Publications
2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Katz E, Gries K, Schecter J, Lendvai N, Slaughter A, Lonardi C, Deraedt W, Costa Filho O, Patel N, Florendo E, Ho K, Karlin L, Weisel K. Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. Journal Of Patient-Reported Outcomes 2026 PMID: 41824255, DOI: 10.1186/s41687-026-01034-z.Peer-Reviewed Original ResearchAltmetricConceptsKnown-groups validityPatient-reported outcomesDiscriminant validityImpact scoresPatient-reported outcome measuresDisease-specific patient-reported outcomeMultiple myelomaTest-retest reliabilityInternal consistency resultsTotal impact scoreClinical outcome assessmentsConfirmatory factor analysis modelStandard-of-care regimensConstruct validityMeasure symptomsOutcome assessmentMeasurement propertiesTotal scoreResultsIn totalTotal symptomsEvidentiary sourcesCiltacabtagene autoleucelScoresDrug Administration guidanceClinical trialsHodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
Advani R, Kelsey C, Armand P, Bello C, Benitez C, Bond D, Chen W, Cherian S, Czader M, Dabaja B, Daly M, Frosch Z, Gordon L, Hansen N, Herrera A, Hochberg E, Hoppe R, Isufi I, Johnston P, Kelly K, Kenkre V, Kline J, Lynch R, McConathy J, Morgan D, Niu A, Paul S, Rabinovitch R, Salavati A, Sano D, Shah H, Spinner M, Svoboda J, Winter J, Yahalom J, Yang J, Montgomery S, Stehman K. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2026, 24: 41-60. PMID: 41671432, DOI: 10.6004/jnccn.2026.0006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsNCCN Clinical Practice GuidelinesHodgkin lymphomaClinical practice guidelinesNCCN guidelinesRelapsed/refractory classical Hodgkin lymphomaTreatment of Hodgkin lymphomaClassical Hodgkin lymphomaPractice guidelinesMultidisciplinary recommendationsLymphomaClinical trialsHodgkinNCCNOncologyGuidelinesDiagnosis
2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Cahill K, Godfrey J, Nabhan C, Kline J, Riedell P, Cohen K, Narula S, Karrison T, Robertson J, Karmali R, Venugopal P, Kim S, Rapoport A, Lee S, Law J, Fishkin P, Isufi I, Velasco M, Kaminer L, Smith S. A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Advances 2025, 9: 5665-5675. PMID: 40720747, PMCID: PMC12848333, DOI: 10.1182/bloodadvances.2025017092.Peer-Reviewed Original ResearchCitationsConceptsDiffuse large B-cell lymphomaDA-EPOCH-RProgression-free survivalDose-adjusted EPOCH-REPOCH-RResponse rateEfficacy criteriaRandomized trialsMulticenter phase 1/2 studyLarge B-cell lymphomaBenefit of lenalidomidePhase 1/2 studyTrial of lenalidomideMedian Follow-UpB-cell lymphomaMyc-driven lymphomasFifty-five patientsDeregulation of MYCR-CHOPBCL2 rearrangementNeutropenic feverOverall survivalPrimary malignancyStage III/IVInferior outcomesCRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
Hunter B, Lunning M, Shadman M, Ahmed S, Abramson J, Perales M, Ahmed N, Mirza A, Isufi I, Frigault M, Crombie J, Miklos D, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini M, Kamdar M. CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation And Cellular Therapy 2025, 32: 171.e1-171.e12. PMID: 41235976, PMCID: PMC13012614, DOI: 10.1016/j.jtct.2025.10.024.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCytokine release syndromeMedian time to resolutionTime to resolutionChimeric antigen receptorClinical trialsLiso-celB cellsCenter for International Blood and Marrow Transplant Research (CIBMTR) registryB-cell lymphomaReal-world settingsLisocabtagene maraleucelTherapy infusionT cellsAntigen receptorInfusionPatientsTrialsTreatment accessPatient safety monitoringDaysOutcomesLymphomaSyndromeReceptorsClinicWeekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Sethi T, Kothari S, Girardi M, Foss F. Weekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome. British Journal Of Haematology 2025, 207: 2140-2142. PMID: 40968584, DOI: 10.1111/bjh.70147.Peer-Reviewed Original ResearchAltmetricNivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
Mei M, Palmer J, Lee H, Isufi I, Chen R, Tsai N, Armenian S, Godfrey J, Song J, Baird J, Thiruvengadam S, Samara Y, Flores J, Peters L, Rosen S, Kwak L, Forman S, Herrera A. Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma. HemaSphere 2025, 9: e70126. PMID: 40313510, PMCID: PMC12042211, DOI: 10.1002/hem3.70126.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAutologous stem cell transplantationProgression-free survivalOverall survivalRr-cHLSalvage regimenHodgkin lymphomaAnti-PD-1 antibodyEffective salvage regimenRelapsed/Refractory Hodgkin LymphomaImmune-related toxicitiesPatients discontinued treatmentHigh-risk diseaseStem cell transplantationLugano classificationRefractory cHLExtranodal diseasePost-ASCTB symptomsFrontline therapyResponding patientsBrentuximab vedotinCR rateB. PatientsCell transplantationPrimary endpointImpact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
VanOudenhove J, Liu Y, Nelakanti R, Kim D, Busarello E, Ovalle N, Qi Z, Mamillapalli P, Siddon A, Bai Z, Axtmayer A, Corso C, Kothari S, Foss F, Isufi I, Tebaldi T, Gowda L, Fan R, Seropian S, Halene S. Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant. PLOS ONE 2025, 20: e0320744. PMID: 40294012, PMCID: PMC12036906, DOI: 10.1371/journal.pone.0320744.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationMemory T cellsStem cell transplantationCell transplantationT cellsSARS-CoV-2Hematopoietic stem cell transplant recipientsAntigen-specific T-cell activationSARS-CoV-2 mRNA vaccinesSARS-CoV-2 vaccine responsesSevere diseaseAnti-spike IgGT cell activationAdaptive immune responsesRobust antibody responsesPost-vaccination responseSARS-CoV-2 infectionMRNA vaccine seriesSingle-cell RNAMyeloablative chemotherapyCellular responsesImmune profileVaccine responseCOVID-19 infectionMRNA vaccinesPatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, PMCID: PMC12321245, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically Meaningful ImprovementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
2024
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e96-e102. PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaAddressing platelet insecurity – A national call to action
Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, PMCID: PMC11921857, DOI: 10.1111/trf.17987.Peer-Reviewed Original ResearchCitations
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
IRB ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsLong-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
IRB ID2000029882RolePrincipal InvestigatorPrimary Completion Date11/30/2036Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
IRB ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
IRB ID2000028478RolePrincipal InvestigatorPrimary Completion Date07/30/2023Recruiting ParticipantsManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
IRB ID2000025634RolePrincipal InvestigatorPrimary Completion Date07/06/2023Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Honors
honor ASCO/AACR Methods in Clinical Cancer Research Workshop Fellow, Vail, CO
08/01/2008National AwardAACRDetailsUnited Stateshonor Outstanding House Officer in Internal Medicine Award
10/01/2007Other AwardAlbert Einstein College of Medicine/Montefiore Medical CenterDetailsUnited Stateshonor The Kijeon Yoo Award for Determination in Pursuit of a Medical Education
10/01/2004Other AwardStony Brook University School of MedicineDetailsUnited Stateshonor Medical School Merit-Based Scholarship
10/01/2004Other AwardStony Brook University School of MedicineDetailsUnited States
News & Links
Copy Link
News
- March 31, 2025
Yale’s Post ASH Review: Highlights from the 2024 American Society of Hematology Annual Meeting
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- July 30, 2024
Smilow Cancer Hospital Cellular Therapies Program
- November 08, 2023
Smilow Shares with Primary Care: Lymphadenopathy and Diagnosis
Get In Touch
Copy Link